Lupin Limited — PPTs, 06-08-2025: Investor Presentation

Here's a summary of Lupin Limited's Q1 FY26 results:

**1. Financial Highlights:**

Lupin delivered strong Q1 FY26: Sales up 12% YoY to ₹6,163.8 Cr. EBITDA surged 52% to ₹1,641.4 Cr (26.6% margin), Net Income grew 28% to ₹1,219.1 Cr. US sales reached $282 Mn (+22% YoY), India sales ₹2,089.4 Cr (+7.8% YoY).

**2. Strategic Initiatives & Growth Drivers:**

Strong push into complex generics & biosimilars. Plans include 15+ US filings and 20+ India launches this fiscal. Aim to generate 65% of new product revenue from complex assets by FY30. Also exploring M&A/in-licensing, notably for GLP-1s.

**3. Business Developments:**

Key launches: US Tolvaptan tabs (180-day FTF exclusivity) and US FDA approval for Rivaroxaban. Several out-licensing deals secured for Ranibizumab, Certolizumab Pegol, and Tiotropium DPI globally. India consumer business carved out.

**4. Market Position & Competitive Advantage:**

Global leader: #3 US generics (prescriptions), #8 in India. Operates in 100+ countries. Advantage from robust R&D (848 patents), leadership in key therapy areas, and continuous quality/compliance enhancements.

**5. Investor Implications:**

Excellent Q1 execution and financial uplift. Substantial investment in complex product pipelines indicates strong future growth potential. Improved regulatory compliance de-risks operations. Appears attractive for long-term growth investors.